Clinical Trials Logo

PEG-rhG-CSF clinical trials

View clinical trials related to PEG-rhG-CSF.

Filter by:
  • None
  • Page 1

NCT ID: NCT04518800 Not yet recruiting - Pancreatic Cancer Clinical Trials

PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer

Start date: August 18, 2020
Phase: N/A
Study type: Interventional

A prospective, open, single-arm clinical study to evaluate the efficacy and safety of jinyouli(PEG-rhG-CSF) in the first-line treatment of advanced pancreatic cancer with nab-paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: nab-paclitaxel, 260mg/m2, intravenous infusion for 30 minutes, D1, Q3W. S-1, 80-120mg, PO BID, D1-14, Q3W. (2) patients who met the eligibility criteria were given jinyouli injections 24 hours after the end of intravenous infusion of nab-paclitaxel during the treatment period.

NCT ID: NCT03776604 Recruiting - Clinical trials for Small Cell Lung Cancer

PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

Evaluation of the efficacy and safety of Jinyouli in preventing neutropenia in multiple chemotherapy cycles in elderly patients with small cell lung cancer through a multicenter, open, one-arm study Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria, chemotherapy regimen: etoposide: 100 mg/m2, d1-3, carboplatin: AUC=5, d1, q21d, prophylactic use test 48 h after chemotherapy Drug PEG-rhG-CSF.